Undisclosed MC4R agonist / Superluminal Medicines - LARVOL DELTA

Superluminal Medicines Announces Oversubscribed $60 Million Series B Financing to Advance Lead Program in Rare Genetic Forms of Obesity into the Clinic (PRNewswire) - "Superluminal's lead clinical program is a selective, biased MC4R agonist being developed for rare genetic forms of obesity and hypothalamic obesity, with a Phase 1 clinical trial expected to begin by the end of 2026."

Financing • New P1 trial • Hypothalamic Injury-associated Obesity

Superluminal Medicines Announces a Selective, Biased, MC4R Agonist is Advancing to IND-enabling Studies for the Treatment of Obesity (PRNewswire) - "IND submission expected in the second half of 2026...Superluminal Medicines...today announced the initiation of IND-enabling studies for its lead program. Superluminal's compound is an orally administered, highly selective, biased MC4R agonist initially targeting rare genetic forms of obesity and hypothalamic obesity, with potential as a treatment for general obesity in combination with GLP-1 drugs....In preclinical studies, the molecule demonstrated high selectivity against MC1R and a favorable safety profile. Additionally, combining MC4R agonists with incretin-targeting drugs has demonstrated a synergistic effect, resulting in a dose-dependent increase in weight loss."

IND • Preclinical • Obesity